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PUBLIC INTEREST STATEMENT
Lichen planus is a skin condition which has been named as it resembles the "lichens" in the plant world. It is an itchy, chronic problem which can go on for years as it can be difficult to control and the itching can be distressing for those affected. In some patients, it can cause significant scarring. Although various treatment options have been used in the treatment of lichen planus, it is still challenging to choose the most effective one. In this investigation, all topical treatments used were evaluated so that both doctors and patients could be better informed about their choices. It was found that topical steroids, the first line of treatment for lichen planus, have not been investigated enough to prove that they work. Light therapy in the form of ultraviolet light has been shown to be effective and should be used before embarking on oral treatments for lichen planus.
Introduction
Lichen Planus (LP) is a chronic inflammatory immune-mediated disease that more frequently affects the skin and oral mucosa (Le Cleach and Chosidow, 2012; Gorouhi, Davari, & Fazel, 2014) . Other areas that may be affected include the scalp, hair, nails and mucous membranes of the genitalia, oesophagus and conjunctiva (Le Cleach and Chosidow, 2012) . The global prevalence of LP is estimated to be in the range of 0.22-5% of the population (Gorouhi et al., 2014) . LP occurs in all age groups but affects adults significantly more than children (Gorouhi et al., 2014; Payette, Weston, Humphrey, Yu, & Holland, 2015) . The disease, although not gender specific has been reported to affect more women than men . Cutaneous lichen planus (CLP) presents as the traditional 6 "P's" of LP-pruritic, purple, polygonal, planar, papules and plaques, frequently affecting the flexures of the extremities (Gorouhi et al., 2009; Usatine & Tinitigan, 2011) . Variants of CLP are site specific and include hypertrophic, pigmentosus, annular, atrophic, follicular, linear or actinic forms on skin surfaces . Generally, CLP is largely managed based on clinical experience, location and severity of the lesions, most of which resolve spontaneously within a few years . Despite treatment, recurrence is common (Usatine & Tinitigan, 2011) . Generalised eruptions have reported to heal faster than limited cutaneous disease. Hypertrophic LP is typically unrelenting (Gorouhi et al., 2009) .
CLP is associated with intense itching and often pigmentation, which affects the patients quality of life due to discomfort and cosmetic problems (Gorouhi et al., 2009 ). Despite numerous medicines available for the treatment of CLP, there exists a gap in the knowledge of recommended drugs as many of the prescribed treatments lack conclusive evidence for efficacy, accompanied by side effects and often produce disappointing results.
There have been four systematic reviews (SRs) (Antiga, Caproni, Parodi, Cianchini, & Fabbri, 2014; Atzmony, Reiter, Hodak, Gdalevich, & Mimouni, 2016; Cribier, Frances, & Chosidow, 1998; Fazel, 2014) and four review articles (Asch & Goldenberg, 2011; Lehman, Tollefson, & Gibson, 2009; I. Manousaridis, Manousaridis, Peitsch, & Schneider, 2013; Puza & Cardones, 2017) published over the past three decades which help in ascertaining evidence of efficacy of many treatment modalities. However, due to the varying inclusion and exclusion criteria amongst these reviews, and the advent of newer treatments being tested, no consolidated publication exists which provides reports of evidence of all types of studies carried out for CLP. This two-part overview presents the findings from all previously published SRs and reviews, including studies that have been omitted in these publications for unidentified reasons and novel studies that have become evident subsequent to these publications.
Part 1 addresses the current literature focusing on topical therapies and phototherapy for the treatment of CLP. Part 2 encompasses all systemic treatments for CLP. The aim is to provide clinicians with a summarised and consolidated evidence of the various treatments of CLP; hence most of the treatments have been tabulated providing information on the type of study, dosage used, study sizes, outcome, as well as the category of evidence.
Methodology

Data sources and search strategy
Related literature published up until January 2018 were obtained from the following electronic database searches: Cochrane Library, Google Scholar, Medline, PubMed, EBSCOHost and ScienceDirect. The following search terms were transcribed to yield articles of relevance:
"cutaneous lichen planus", "treatment", "systematic review" and "review" in combination with; "topical treatment", "systemic treatment", "UV light/phototherapy"; "low molecular weight heparin", "alternative/complementary medicine", "calcineurin inhibitors". Screening of the literature was performed independently by two authors (YT and RM) in order to validate the reliability of the information and prevent author bias. Reference lists of included papers were scanned, and further relevant publications were retrieved. This review presents findings of all studies including the most recent current literature available.
Inclusion and exclusion criteria
We included all English studies that have been previously published in peer-reviewed journals up to January 2018. There was no restriction for the type of study and hence we included randomised controlled trials (RCTs), non-randomised control studies, cohort studies, case series, case reports and anecdotal studies. We included the following clinical subtypes of CLP-hypertrophic, pigmentosus, annular, atrophic, follicular, linear or actinic. Studies of oral lichen planus with cutaneous involvement were also included. We excluded those studies that focused on solely oral involvement without cutaneous lesions, lichen planopilaris, palmoplantar and lichen pemphigoids.
Formulation of study strategy
Upon retrieval of all published literature, CLP studies were collated according to the treatment modalities. We found four systematic reviews (SRs) (Antiga et al., 2014; Atzmony et al., 2016; Cribier et al., 1998; Fazel, 2014) and four review articles (Asch & Goldenberg, 2011; Lehman et al., 2009; Manousaridis et al., 2013; Puza & Cardones, 2017 ) published on CLP including additional studies not mentioned by the current reviews. To date, the most recent published SR by Atzmony et al. (2016) was used as a benchmark to compare data from previously published SRs and reviews, in addition of any relevant old or current literature obtained. Table 1 provides a summary of the criteria of selection of scientific publications for each SR and review previously published.
Level of evidence grading
Three different grading systems were used to describe the level of evidence in the various SRs. These included the Grading of Recommendation, Development and Evaluation (GRADE) system, American College of Physicians (ACP) guidelines grading system and Sackett's system of grading (Table 1) . For the purpose of standardisation for evidence-based medicine, we used the GRADE system (Guyatt et al., 2008) to categorise each study. The GRADE system offers an explicit and comprehensive grading criterion and provides clear characterisation of the levels of evidence and strength of recommendation for clinicians (Guyatt et al., 2008) . Where studies were already graded (as in the respective SRs), we represented it using the GRADE format for consistency. The level of evidence is based on the quality of the study i.e. study design, consistency and degree of specificity. These are graded as High, Moderate, Low and Very Low. The strength of recommendation is graded as either strong or conditional (weak), based on the treatment outcome in individual studies (Guyatt et al., 2008; Schunemann, Hill, Guyatt, Akl, & Ahmed, 2011) .
• High level of evidence is allocated to studies that have a controlled trial study design which minimises the risk of bias and have a high confidence that the true effect may coincide with the estimated effect.
• Moderate level studies are in line with high level of evidence but there may be a possibility of change in the estimate.
• Low level of evidence may have limited confidence on the estimate of effect, while Very low levels of evidence in studies that have minimal confidence and that the true effect may be substantially different from the estimate of effect. 
Treatment regimens
Topical interventions for cutaneous lichen planus
Topical treatments for CLP include corticosteroids, calcineurin inhibitors e.g. tacrolimus and Vitamin D3 analogues, e.g. calcipotriol. Also included in this review are phototherapy treatments.
Topical corticosteroids
Class 1 (ultra-high potency) and Class II (high potency) topical corticosteroids are still considered the first line of treatment for CLP due to their anti-inflammatory properties that focus on localised lesions and reduce pruritus (Ramachandran, 2014) . Six studies on topical corticosteroids were identified in the literature. Only one RCT was reported by Atzmony et al. (2016) which included betamethasone valerate 0.1% vs calcipotriol. In addition to that, four studies reported in the Atzmony et al. SR were non-randomised case-control trials (Atzmony et al., 2016) . Two studies conducted before 1970 were reported by Cribier et al. (1998) but were excluded by Atzmony et al. (2016) . A preceding study conducted in 1976 by Björnberg and Hellpen (1976) was only reported in a review by Manousaridis et al. (Hazra et al., 2013) .
Upon evaluations of studies that explore the effectiveness of topical corticosteroids, it is apparent that majority of these studies have low patient sample size with the largest study group of 25 patients. Only a single RCT was conducted (Theng et al., 2004) , following two non-RCTs (Chopra, Mittal, & Kaur, 1999; Sharma & Mishra, 2003) , two open, non-comparative trials (Björnberg & Hellpen, 1976; Marsden, 1968) and one case-controlled study (Brock & Cullen, 1967) . Results varied across studies with different corticosteroid formulations used. Response across each of these studies demonstrated no significant difference with a lower response between the topical corticosteroid betamethasone valerate 0.1% and topical calcipotriol (Theng et al., 2004) . Similarly, with betamethasone diproprionate 0.05%, no significant difference was observed in a comparison against PUVAsol (Sharma & Mishra, 2003) . Furthermore, in an open trial by Björnberg and Hellpen (1976) , a large effect (73.7% improvement) with betamethasone-17,21-diproprionate 0.05% was demonstrated, although there was no comparative measure (Björnberg & Hellpen, 1976) . Other studies with topical fluocinonide acetonide reported a low (28.6%) complete response (Marsden, 1968) and with triamcinolone 0.5%, a lower percentage of patients had a better response with the topical steroid (Brock & Cullen, 1967) . Topical Clobetasol propionate lotion together with a hydrocolloid occlusive dressing was used in patients with chronic skin diseases including CLP. It was reported that in those patients with CLP, 2.8 weeks was the average time to remission (Volden, 1992) .
Grading of the studies showed that none of the studies published reported a high level of evidence. Apart from the one RCT conducted by Theng et al. (Theng et al., 2004) , all other studies demonstrated either a low or very low level of evidence. Considering that no high-level evidence exists for the use of topical corticosteroids in CLP, its routine use by clinicians as first-line treatment for CLP is primarily based on their own experiences. The use of topical corticosteroids under occlusion and intra-lesional corticosteroid injections are primarily anecdotal and there are no published trials demonstrating their efficacy. The strength of recommendation for topical corticosteroids is discretionary, and its role as first-line therapy is therefore arguable. Table 2 provides a summary of all published topical corticosteroid studies to date.
Phototherapy
Phototherapy is often used in the treatment of various inflammatory skin disorders (Vangipuram & Feldman, 2016) . It is a specialised technique that can act as an alternative treatment to assist in clearing of lesions observed in CLP. The mechanism of its action is controversial since sunlight is known to aggravate certain variants of CLP (Taneja & Taylor, 2002) , although at different wavelengths, treatment using phototherapy is widely explored. Following the very first SR in 1998 by Cribier et al. (1998) , only one RCT on phototherapy was conducted by Iraji et al. (2011) and reported in the three subsequent SRs (Antiga et al., 2014; Atzmony et al., 2016; Turan et al., 2009 reported on three non-RCTs, and although part of the inclusion date, this SR did not include the Gonzalez, Momtaz-T, and Freedman (1984) study in 1984 which was reported by Cribier et al. (1998) . Further studies which were predominately case series, non-comparative open trials and retrospective studies were reported in SRs by Cribier et al. (1998) and Antiga et al. (2014) . These studies did not meet the Atzmony et al. (2016) SR inclusion criteria.
Additionally, we found the other two studies (case series), which explored the efficacy of phototherapy, that were not mentioned in any of the SRs and reviews despite meeting their inclusion criteria. One older study by Gamil, Nassar, Saadawi, El-Qashishi, and Ahmed (2009) and a novel treatment by Fan et al. (2015) . A four-year retrospective study by Solak, Sevimli Dikicier, and Erdem (2016) which demonstrated a significant positive response with NBUVB for generalised lichen planus was only reported in the Puza and Cardones review (Samycia & Lin, 2012) . Table 3 summarises all documented phototherapy studies.
Ultraviolet B (UVB) therapy
Commonly used in the treatment of CLP, Narrow-band UVB (NBUVB) and Broad-band UVB (BBUVB) radiation exposure are known to reduce skin lesions by causing apoptosis of the affected cells and interfering with immunological functions that inhibit the expression of related inflammatory factors (Berneburg, Röcken, & Benedix, 2005) . Post 2002 and to date, there were seven published studies conducted with NBUVB with sample sizes up to a maximum of 43 patients. Results from the only RCT conducted with phototherapy demonstrated that NBUVB had a better response to systemic prednisolone therapy (Iraji et al., 2011) . This evidence was considered moderate. NBUVB was compared to oral PUVA in one non-RCT where it was reported to be comparable to oral PUVA (Wackernagel et al., 2007) . The evidence of efficacy was considered low. Three case series demonstrated a positive response to NBUVB. Evidence of efficacy from these was very low (Gamil et al., 2009; Saricaoglu, Karadogan, Baskan, & Tunali, 2003; Taneja & Taylor, 2002) . Three retrospective studies, although regarded as low evidence studies, reported a favourable outcome for NBUVB treatment; two of which were non-comparative studies by Solak et al. (Majid, 2017) and Habib et al. (2005) , with one comparative to BBUVB reported by Pavlotsky, Nathansohn, Kriger, Shpiro, and Trau (2008) .
Despite the level of evidence in majority of studies with NBUVB being considered low, an improved outcome with NBUVB was reported in six of the seven studies. In only one study, NBUVB was comparable to oral PUVA in the long term in terms of efficacy and relapse rates, with oral PUVA demonstrating an initial superior response. Oral PUVA may have a better response in patients with hypertrophic LP who do not respond to NBUVB. The recommendation based on these results is that NBUVB should be considered as an effective treatment option for CLP before proceeding to use systemic corticosteroids or systemic immunosuppressants. However, the high costs associated with outpatient phototherapy and the frequency of sessions required, need to be considered.
Psoralen plus Ultraviolet A (PUVA) therapy
Photochemotherapy using Ultraviolet A light in conjunction with psoralen (as a photosensitizer) enhances the efficacy of UVA in the treatment of CLP (Vangipuram & Feldman, 2016) . There are no RCTs with psoralen plus ultraviolet A (PUVA) reported, with either oral or bath therapy. Although, one non-RCT conducted in 1987 by Helander, Jansen, and Meurman (1987) established that there is no significant difference between oral PUVA and bath PUVA with no significant difference in the long-term outcomes between PUVA and no treatment. In contrast to NBUVB, while oral PUVA initially showed a clinically better response, there was a very similar overall response in long term observation (Wackernagel et al., 2007) . Sharma and Mishra (2003) reported that PUVA is comparable to treatment with topical betamethasone and cetirizine combined. In other studies, a favourable response to PUVA was evident in one non-RCT (Gonzalez et al., 1984) and four case series (Karvonen & Hannuksela, 1985; Kerscher, Volkenandt, Lehmann, Plewig, & Röcken, 1995 Randomised control trial (RCT), minimal erythema dose (MED), Three times daily (tds), Not stated (NS) and 1995. The level of evidence in these studies with PUVA is considered low. PUVA is not considered the ideal choice of treatment for CLP. NBUVB is a preferred phototherapeutic option however patients that do not respond well to NBUVB may be susceptible to PUVA treatment.
Laser diode therapy
A novel treatment for CLP in a 2015 study by Fan et al. (2015) examined the use of photodynamic therapy with 10% 5-aminolevulinic acid (ALA) cream mediated under photodynamic therapy (PDT). The study consisted of seven CLP patients who were previously recalcitrant to topical steroid creams. ALA cream was applied to affected lesions and then incubated for 3 h after which irradiation using 635nm laser diode was used to target affected areas. The majority (71%) demonstrated complete response to treatment in which complete disappearance of the lesions was observed. The remaining two patients exhibited partial response. Patients demonstrated complete response after just one course consisting of two-week intervals of three sessions. After 6 months follow up, there was no recurrence in those who had complete response to treatment. The side effects experienced were pain and burning sensations which were tolerable with the use of a topical lidocaine spray. Moderate erythema was observed during recovery and clearing was seen within 10 days. The mechanism on how treatment action occurs on the skin is unclear but may accelerate apoptosis of targeted affected cells.
Considering high relapses with other treatments, associated side effects with high potency steroids and possible carcinogenic side effects with constant PUVA exposure; ALA-mediated PDT provides a minimal invasive treatment option with little side effects and recurrence. Larger studies are required to confirm its efficacy and understand its mechanisms (Fan et al., 2015) .
Fractional CO 2 laser
In a recent study (Majid, 2017) in patients with hypertrophic LP, complete resolution of lesions was found with the use of fractional CO 2 laser-assisted corticosteroid delivery. This was administered at 4-week intervals (60 J/cm 2 ) in combination with either triamcinolone suspension 10mg/ml or topical clobetasol propionate gel applied to the lesion immediately after laser treatment and then twice daily. Topical corticosteroid alone was not very effective as a stand-alone treatment, but fractional CO 2 complete relief was observed with noticeable improvement in skin lesions. This study shows that treatment with corticosteroids is more effective in CO 2 laser assisted drug delivery.
Topical calcineurin inhibitors (TCIs)
Topical calcineurin inhibitors (TCIs) are widely explored as a potential substitute for corticosteroids because of the potent side effects of corticosteroids in dermatological treatment. Their immunomodulatory and anti-inflammatory properties are attributed to the inhibition of the protein calcineurin phosphatase, which is known to regulate cytokine production and T-cell activation (Wong & Kurian, 2016) . Despite the strong evidence of its use in double-blind and open studies for oral lichen planus (More et al., 2017) , there are no trials on calcineurin inhibitors for CLP that were reported in any of the SRs or reviews. The only SR to mention treatment of CLP using calcineurin inhibitors was by Fazel (2014) . The studies were sourced from an SR by Samycia and Lin (2012) for the treatment of CLP using TCIs however no analysis of the included studies from this was reported by Fazel (2014) . Samycia and Lin (2012) identified 1 open prospective trial, 11 case reports and 1 case series of TCIs and discusses their efficacy in various types of CLP. We identified an additional study which was not included in the Samycia and Lin (2012) SR on TCIs by Coman, Benea, and Georgescu et al. (2005) who had explored the use of 1% pimecrolimus for LP treatment. The level of efficacy for all of the individual reports was considered very low.
From all 11 studies evaluating the efficacy of tacrolimus, ineffective treatment was reported in only one study which treated for classic LP and LPP (Kim et al., 2008) . A positive response was noted in all remaining studies with tacrolimus. Pimecrolimus was effective in all 3 case reports. Improved study designs which are randomised and controlled with larger patient numbers are required to define and formalise the role of calcineurin inhibitors in CLP. Based on the findings from numerous reports and its mechanism of inhibition of cytokine production and proliferation which in turn limits T-cell propagation, it may be advisable to use topical calcineurin inhibitors in CLP in conjunction with topical steroids and thereby possibly reducing the need for long term topical steroids. Table 4 summarises all reported topical calcineurin inhibitor studies.
Topical cyclosporin
Topical cyclosporin acts as an immunomodulatory drug which suppresses the direct effects of T-lymphocytes that are associated with immunoregulatory dysfunctions associated with CLP (Faulds, Goa, & Benfield, 1993) . Only one study of 5% w/v intravenous cyclosporin (Grattan, Boon, & Gregory, 1989) used topically under occlusion was reported in the study by Cribier et al. (1998) . This was a case series of four chronic hypertrophic LP patients. Improvement was noted in all patients. No further studies were conducted using intravenous cyclosporin topically since 1989. Evidence for its use is thus very low. Long term use of cyclosporin is not advised as renal toxicity and arterial hypertension may occur. Minimising the dosage may reduce the risk of adverse effects (Dehesa, Abuchar, Nuno-Gonzalez, Vitiello, & Kerdel, 2012) . Results are summarised in Table 5 .
Vitamin D 3 analogues
Vitamin D 3 analogues have shown to have immunomodulatory properties affecting cell growth and have been used in clinical trials for the treatment of CLP (Turan et al., 2009 ). We identified a total of three RCTs using topical Vitamin D 3 analogues, specifically, calcipotriol and KH1060 (Vitamin D 3 analogue) of the treatment of CLP. Only one RCT by Theng (Theng et al., 2004) using calcipotriol treatment was reported by Atzmony et al. (2016) . The remaining two RCTs that explored the efficacy of KH1060 were included in the SR by Fazel (Turan et al., 2009) . Furthermore, one open study using calcipotriol by Bayramgürler, Apaydın, and Bilen (2002) was reported in a review by Puza (Ansari et al., 2017) .
All three RCTs with moderate to high level of evidence showed no significant difference between topical Vitamin D 3 to placebo or betamethasone valerate. Vitamin D 3 analogues are therefore not a strongly recommended treatment for CLP. It is further suggested by Berneburg et al. (2005) that the combination treatment of Vitamin D3 in conjunction with phototherapy may enhance efficacy of treatment outcomes. Table 6 summarises all studies with topical Vitamin D 3.
Conclusion
Despite various treatment modalities available, CLP remains a therapeutic challenge. On analyses from previously published literature, we identified studies not reported on and included newly published evidence. For topical treatment options, we report on all available clinical trials, however, the quality of evidence of many of the treatments remain low. Attributable to the fact that large randomised prospective controlled trials with rigorous methods are insufficient, we rely on evidence from single RCTs if conducted, smaller trials, non-randomised trials, retrospective studies as well as case series and reports. Although the level of evidence is low in the majority of studies, our recommendation for use is based on a combination of factors including side effects, patient satisfaction and cost-effectiveness.
While routinely used as first-line treatment for CLP by clinicians, strong evidence that supports the use of topical corticosteroids is absent and its role as first-line therapy is controversial. NBUVB is the preferred phototherapeutic treatment option for CLP and should be considered before commencing with systemic treatment. Vitamin D 3 is not recommended for the treatment of CLP due to poor patient outcomes. TCIs show promising results despite evidence only available from case reports. Once-off studies with novel treatments like ALA-mediated PDT (Fan et al., 2015) for localised lesions, fractional CO 2 laser (Majid, 2017) and intravenous cyclosporine (Grattan et al., 1989) Randomised control trial (RCT), Not stated (NS), bds (twice daily).
no available evidence exploring the efficacy of these treatments in CLP. The second part of this review will investigate the efficacy of systemic treatments for CLP in the current literature.
